Back

Safety and efficacy of a phase 1 clinical gene therapy trial in patients with advanced heart failure using a rationally designed cardiotropic AAV vector targeting protein phosphatase inhibitor-1

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Lothar Roessig

Research Triangle Park (United States of America)

6 More presentations in this session

Presentation thumbnail
Renin-angiotensin-aldosterone system inhibitor discontinuation and its impact on one-year mortality in heart failure patients with acute kidney injury: a propensity matched analysis
Doctor D. Feldman (Newark, US)
Abstract Slides Video
Presentation thumbnail
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
Doctor A. Stefanini (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Initial safety of targeted immune activation with the amyloid depleter ALXN2220
Professor T. Damy (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Age-stratified and sex-stratified effect of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction-data from PARADE-HF: nationwide medication adherence study
Doctor M. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Safety, tolerability, and efficacy of uptitration of guideline-directed medical therapy for acute heart failure stratified by baseline risk
Doctor A. Chang (San Francisco, US)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
thumbnail
Congress Presentation
GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure
thumbnail
Congress Presentation
PKP2 gene therapy reduces ventricular arrhythmias, reverses ventricular remodeling, improves heart function, and reduces mortality in a mouse model of arrhythmogenic right ventricular cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources